title: Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking.
abstract: OBJECTIVE
  Ergot-derived dopamine agonists (EDDA) induce fibrotic heart valve disease. We aimed to investigate whether EDDA treatment also affects left ventricular (LV) function.
  
  
  RESULTS
  Myocardial function was evaluated in 110 Parkinson patients [mean age (63.4 +/- 9.0 years)] treated for at least 6 months with either EDDA (n = 71) or non-EDDA (n = 39). LV ejection fraction did not differ between EDDA and non-EDDA patients [63 +/- 4% vs. 65 +/- 4% (ns)]. There was no difference in prevalence of diastolic dysfunction between EDDA and non-EDDA patients [7% vs. 8% (ns)]. Finally, averaged LV systolic myocardial strain and longitudinal displacement analysed by means of two-dimensional speckle tracking showed no difference between EDDA and non-EDDA patients [strain: 19 +/- 3% vs. 19 +/- 2% (ns) and longitudinal displacement: 12 +/- 2 mm vs. 12 +/- 2 mm (ns)]. Elevated p-NT-proBNP was found in 38% of EDDA patients and in 59% of non-EDDA patients (ns).
  
  
  CONCLUSIONS
  In contrast to the well-established association between EDDA treatment and valvular fibrosis, EDDA did not have a detectable adverse impact on myocardial systolic and diastolic function.
authors.affiliation: Department of Cardiology, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark.
authors.forename: Vibeke Guldbrand
authors.initials: VG
authors.lastname: Rasmussen
authors.forename: Steen Hvitfeldt
authors.initials: SH
authors.lastname: Poulsen
authors.forename: Erik
authors.initials: E
authors.lastname: Dupont
authors.forename: Karen
authors.initials: K
authors.lastname: Ostergaard
authors.forename: Gholamhossein
authors.initials: G
authors.lastname: Safikhany
authors.forename: Henrik
authors.initials: H
authors.lastname: Egeblad
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D003971:Diastole; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004452:Echocardiography / Q000379:methods*; D018619:Echocardiography, Doppler, Pulsed; D004878:Ergotamine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006349:Heart Valve Diseases / Q000000981:diagnostic imaging; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010300:Parkinson Disease / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy; D012189:Retrospective Studies; D013599:Systole; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D015415:Biomarkers; D018491:Dopamine Agonists; D020097:Natriuretic Peptide, Brain; D004878:Ergotamine